



September 2020 Volume 70 ISSN 1479-6848 (online)




22nd European Congress of Endocrinology

5-9 September 2020, European Society of Endocrinology













Volume 70 September 2020

22nd European Congress of Endocrinology

5-9 September 2020, European Society of Endocrinology

EDITORS

Abstracts were marked by the Abstract Marking Panel and selected by the Programme Organising Committee

e-ECE 2020 Mini-Programme Organising Committee

Andrea Giustina (Italu). ESE President Martin Reincke (Germanu). ESE President-Elect Bulent Yildiz (Turkey), ESE Treasurer (until May 2020) Riccarda Granata (Italy), ESE Congress Committee Chair

Programme Organising Committee

Riccarda Granata (Italy), ESE Congress Committee Chair Jens Otto Lunde Jørgensen (Denmark), Clinical Co-Chair Attila Balázs Patócs (Hungary), Basic Science Co-Chair Michal Kršek (Czech Republic). Local Organising Committee

Zhanna Belava (Russian Federation) Nienke Biermasz (The Netherlands) Jens Bollersey (Norway)

Ex Officio Members

Andrea Giustina (Italu), ESE President Martin Reincke (Germany), ESE President-Elect Bulent Yildiz (Turkey), ESE Treasurer (until May 2020) Wiebke Arlt (UK), Editor in Chief, European Journal of Endocrinology

Attila Balázs Patócs (Hungary), 2020 POC Co-Chair Jens Otto Lunde Jørgensen (Denmark), 2020 POC Co-Chair Daniela Cota (France), 2021 POC Co-Chair Lars Rejnmark (Denmark), 2021 POC Co-Chair

Daniela Cota (France) Ashley Grossman (UK) Csilla Krausz (Italu) Madalina Musat (Romania) Uberto Pagotto (Italy) Agnieszka Piekielko-Witkowska (Poland) Vincent Prevot (France) Manel Puig-Domingo (Spain)

Josef Köhrle (Germanu), Editor in Chief, Endocrine Con-

Felix Beuschlein (Switzerland), ESE Clinical Committee Chair Robin Peeters (Switzerland), ESE Science Committee Chair Riccarda Granata (Italy), ESE Congress Committee Chair

M Krsek Czech Republic

Liiliana Marina (Serbia). EYES Chair Manel Puig Domingo (Spain), 2020 POC Member Mónica Marazuela (Spain), ESE Secretary

Lars Rejnmark (Denmark) Mark Sherlock (Ireland) Marily Theodoropoulou (Germany) Pierre Val (France) AJ van der Lely (The Netherlands) Wim van Hul (Belgium) Greisa Vila (Austria) Maria Chiara Zatelli (Italy)

Marek Ruchala (Poland). ECAS Representative Mehul Dattani (UK) (Switzerland), ESPE Representative Luis Cardoso (Portugal), EYES Representative

E Shestakova Russia

M Shestakova Russia

Abstract Marking Panel

Marker Name Country M Alevizaki Greece K Amrein Austria C Andoniadou UK G Assié France S Babajko France C Badiu Romania A Baranowska-Bik Poland A Barlier France K Basham USA A Beckers Belgium P Beck-Peccoz Italy Z Belaya Russia I Bertherat France M Bidlingmaier Germany N Biermasz The Netherlands W Bik Poland K Birkeland Norway K Boelaert UK J Boguslawska Poland I Bollerslev Norway R Bouillon Belgium M Brandi Italy D Branisteanu Romania K Briot France T Brue France G Brunetti Italy C Buchanan UK P Burman Sweden H Butz Hungary S Cannavo Italy J Cap Czech Republic C Capatina Romania M Caprio Italy J Castaño Spain H Cederberg-Tamminen Finland O Chabre France P Chanson France K Chatterjee UK N Cherradi France M Chiara Zatelli Italy F Chiarelli Italy

J Chowen Spain

D Cota France

D Cuthbertson UK

S Christin-Maitre France

M Cohen-Solal France

L Czupryniak Poland J Dahlgen Sweden P Dahlqvist Sweden C Daousi UK M Dattani UK C Dayan UK J de Castro Portugal W de Herder The Netherlands E de Koning The Netherlands W Dhillo UK G Di Dalmazi Germany E Diamanti-Kandarakis Greece C Dieguez Spain E Dirinck Belgium M Donath Switzerland [Drouin Canada L Duntas Greece A Dwyer USA G Eisenhofer Germany V Elian Romania F Fallo Italy M Fassnacht Germany J Favier France R Feelders The Netherlands U Feldt-Rasmussen Denmark F Fernandes Rosa France S Fica Romania E Fliers The Netherlands S Franks UK W Fraser UK [Frystyk Denmark L Fugazzola Italy C Fuß Germany F Gabalec Czech Republic S Gaberšček Slovenia M Gahete Spain R Gärtner Germany B Gatta Cherifi France L Gennari Italy M Gheorghiu Romania I Gherlan Romania P Giacobini France F Giorgino Italy A Giustina Italy M Godlewska Poland I Gomez-Ambrosi Spain D Goulis Greece R Granata Italy C Gravholt Denmark

D Grigorie Romania P Groop Finland A Grossman UK L Groussin France G Gruden Italy L Guasti UK M Haluzik Czech Republic R Hampl Czech Republic V Hána Czech Republic F Hannan UK A Heck Norway M Heikinheimo Finland A Hoeflich Germany L Hofland The Netherlands A Hubalewska-Dydeiczyk Poland I Huhtaniemi UK E Husebye Norway P Igaz Hungary I Ilovayskaya Russia E Isenovic Serbia M Jaffrain-Rea Italy B Jarzab Poland K lazdzewski Poland N Jessen Denmark D Jezova Slovakia G Johannsson Sweden A Jørgensen Norway J Jørgensen Denmark U Kaiser USA G Kaltsas Greece C Kanaka-Gantenbein Greece G Kanakis Greece T Kararup Hansen Denmark D Karasek Czech Republic N Karavitaki UK A Karlsson Sweden S Kaser Austria D Kastelan Croatia J Kaufman Belgium M Keil USA F Kelestimur Turkey R Kineman USA T Kocian Slovenia J Kopchick USA M Korbonits UK B Kos-Kudla Poland

C Krausz Italy

N Krone UK

M Kroiss Germany

A Kurylowicz Poland E Lalli France B Langdahl Denmark B Lapauw Belgium J Laven The Netherlands G Lavery UK L.Laviola Italy I Lazurova Slovakia H Lefebvre France Leger France T Links The Netherlands P Lips The Netherlands S Llahana UK A Luger Austria S Lund Denmark R Luque Spain D Macut Serbia D Maiter France E Mamedova Russia M Mannelli Italy E Mannucci Italy F Mantero Italy G Mantovani ITALY M Marazuela Spain L Marina Serbia N Matikainen Finland C McCabe UK O Meijer The Netherlands L Metherell UK D Miljic Serbia J Mittag Germany N Møller Denmark L Morin-Papunen Finland A Mukherjee UK M Musat Romania E Nagy Hungary S Neggers The Netherlands J Newell-Price UK N Nicolaides Greece D Niculescu M Niedziela Poland R Nogueiras Spain B Obermayer-Pietsch C Olarescu Norway P Oliveira Portugal D Olsson Sweden K Øystese Norway

U Pagotto Italy

N Papanas Greece A Patócs Hungary R Peeters The Netherlands S Pekic Serbia N Pellegata Germany L Perez-Rivas Germany H Perrild Denmark L Persani Italy G Perseghin Italy M Petakov Serbia A Piekiełko-Witkowska Poland V Pirags Latvia C Poiana Romania R Poladian Lebanon S Polyzos Greece P Popławski Poland V Popović Serbia M Porta Italy M Poutanen Finland D Power Portugal M Puig Domingo Spain C Quarta France S Radian Romania O Ragnarsson Sweden N Rahman Finland E Rajpert-De Meyts Denmark M Rauner Germany G Raverot France M Reincke Germany L Reinmark Denmark S Rice UK M Robledo Spain P Rodien France H Romijn The Netherlands C Ronchi Italy R Ross IIK R Roussel France N Rucci Italy M Ruchala Poland E Rutten Belgium D Santi Greece P Saunders - UK C Schalin-Jäntti Finland S Schmid Germany I Schopohl Germany D Schulte Germany P Schwarz Denmark

M Sherlock Ireland

M Simoni Italy I Skrha Austria P Soares Portugal A Solini Italy A Spada Italy I Spranger Germany A Spyroglou Germany G Stalla Germany E Stener-Victorin Sweden C Strasburger Germany C Stratakis USA A Tabarin France T Tankova Bulgaria M Tena-Sempere Spain N Tentolouris Greece M Terzolo Italy M Theodoropoulou Germany CThompson Ireland H Timmers The Netherlands M Toth Hungary P Touraine France R Trifanescu Romania A Tsapas Greece ETsourdi Germany M Tzanela Greece E Valassi Spain G Valk The Netherlands E van den Akker The Netherlands A van der Lely The Netherlands Lvan Eck The Netherlands W van Hul Belgium M Vantyghem France G Vila Austria E Visser The Netherlands I Visser The Netherlands V Volke Estonia J Widimsky Czech Republic W Wiersinga The Netherlands I Wilkinson UK T Williams Germany S Wudy Germany P Yeoh UK B Yildiz Turkey M Zarkovic Serbia M Zennaro France

CONTENTS

e-ECE 2020 22nd European Congress of Endocrinology

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The Geoffrey Harris Prize Lecture	AP1
The European Journal of Endocrinology Prize Lecture	
European Hormone Medal Lecture	
Clinical Endocrinology Trust Lecture	
PLENARY LECTURES	
Exercise as medicine – a translational perspective	PL1
Glucocorticoids in cancer: a new paradigm	
Harnessing the microbiome in metabolic disease	
Mechanisms for SARS-CoV-2 cell entry	
Maternal thyroid hormone and child brain development	
It takes thyroid hormone to make sense	
Effects of EDCs on neuro-endocrine systems and behaviour	
SYMPOSIA	
New horizons in phaeochromocytoma and paraganglioma	S1.3
Osteoporosis and fracture prediction	
Controversial issues in bariatric surgery	-S3.3
Unveiling signatures in pituitary neuroendocrine tumours	S4.3
Hyperthyroidism across the lifespan S5.1-	S5.3
Adrenocortical carcinoma	S6.3
Endocrine disruptors, just a hype or not?	-S7.3
PCOS: from Genetics to Treatment S8.1–	
COVID-19 SESSION	
Endocrine targets related to COVID infection	S1.1
Managing the Cytokine storm	S1.2
How strong is obesity as a risk factor for COVID-19 patients	S1.3
ORAL COMMUNICATIONS	
Adrenal and Cardiovascular Endocrinology OC1.1–Oc	C1.7
Bone and Calcium OC2.1–O	C2.7
Diabetes, Obesity, Metabolism and Nutrition	C3.7
Pituitary and Neuroendocrinology OC4.1–O	C4.7
Thyroid	C5.7
Hot Topics (including COVID -19) OC6.1–O	C6.7
Endocrine-related Cancer OC7.1–O	C7.7
Environmental Endocrinology OC8.1–Oc	C8.6
Reproductive and Developmental Endocrinology	C9.7
Young Investigators	YI12

AUDIO EPOSTER PRESENTATIONS

Adrenal and Cardiovascular Endocrinology	AEP1–AEP121
Bone and Calcium	AEP122–AEP242
Diabetes, Obesity, Metabolism and Nutrition	AEP243–AEP527
Endocrine-related Cancer	AEP528–AEP540, AEP655
Environmental Endocrinology	AEP541-AEP542
General Endocrinology	AEP543-AEP559
Pituitary and Neuroendocrinology	
Reproductive and Developmental Endocrinology	AEP778-AEP856
Thyroid	
Hot topics (including COVID-19)	
EPOSTER PRESENTATIONS	
Adrenal and Cardiovascular Endocrinology	EP1–EP58
Bone and Calcium	EP59–EP123
Diabetes, Obesity, Metabolism and Nutrition	EP124–EP265
Endocrine-related Cancer	EP266–EP270
Environmental Endocrinology	EP271
General Endocrinology	EP272–EP279
Pituitary and Neuroendocrinology	
Reproductive and Developmental Endocrinology	EP374–EP410
Thyroid	
Hot topics (including COVID-19)	EP533_EP589

AUTHOR INDEX

Therefore, we conclude that EMT occurs in some somatotropinomas, but it does not seem to explain their response to SRL in this subset of tumors. However, in the rest of somatotropinoma SNA11 and RORC may predict the response to SRL treatment.

DOI: 10.1530/endoabs.70.AEP729

AEP730

Global methylation-demethylation status in pituitary neuroendocrine tumors as potential therapeutic target

Borbála Szabó¹, Kinga Németh², Katalin Mészáros².3, Nikolette Szücs¹, Sándor Czirják⁴, Lilla Reiniger⁵, AttilaPatócs².3, & Henriett Butz².3,6 ¹Semmelweis University, 2nd Department of Internal Medicine, Faculty of Medicine, Budapest, Hungary; ²Semmelweis University, Momentum Hereditary Endocrine Tumors Research Group, Budapest, Hungary; ³Semmelweis University, National Bionics Program, Budapest, Hungary; ⁴National Institute of Clinical Neurosciences, Budapest, Hungary; ⁵Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary; ⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

Background

The altered DNA methylation of certain genes in Pituitary Neuroendocrine Tumors (PitNETs) are well known. However little information is available regarding global methylation changes and the process of demethylation in these tumors. In addition, influencing global methylation-demethylation could be a potential new therapeutic option especially in clinically non-functional PitNETs.

Material and methods

Overall, 44 fresh frozen pituitary adenoma tissues (29 gonadotroph, 12 somatotroph, 3 corticotroph) were collected and characterized according to the 2017 WHO classification. Decitabine was used to alter global methylation-demethylation status on *in vitro* GH3 and RC-4B/B cell lines. In tissue samples 5-hydroxymethylcytisone (5 hmC), UHRF1-2 protein and Ki-67 were assessed by immunohistochemistry; gene expression of DNA Methyl-transferase (DNMT1), methyl-cytosine dioxygenases (TET1-3) and ubiquitin-like with PHD and ring finger domain (UHRF1-2) were investigated by RT-qPCR. 5-methylcytosine (5 mC) and 5 hmC level were determined by HPLC-MS/MS method.

Results

Decitabine decreased 5-methylcytosine (5 mC) and increased 5 hmC levels *in vitro* in both pituitary cell lines. Parallel, cell proliferation and viability were decreased significantly. UHRF1-2 were also altered upon decitabine treatment *in vitro*. Interestingly, in PitNET tissue samples 5 hmC was gradually decreased in samples with higher Ki-67 index. In samples with different histology UHRF2 showed different expression, while UHRF1 showed gradual increase in adenoma samples with higher Ki-67 index. Additionally, UHRF2 positively correlated with 5 hmC level in pitNET tissues and both UHRF1 and UHRF2 showed significant positive correlation with DNMT1 and TET1-3 expression.

Conclusion

Our results showed that methylation-demethylation process (5 hmC, DNMT1, TET1-3 and UHRF1-2) is closely linked to proliferative behaviour of PitNETs. Altering global 5 mC and 5 hmC level can be a potential, new therapeutic target in therapy resistant pituitary tumors.

Grants and financial support

This work has been funded by the National Program of Bionics (Program Medical Bionics lead by Attila Patócs) and Semmelweis Innovation Found (STIA_19) to Henriett Butz. Henriett Butz is a recipient of Bolyai Research Fellowship of Hungarian Academy of Sciences and ÚNKP-18-4-SE-8 New National Excellence Program of The Ministry of Human Capacities.

DOI: 10.1530/endoabs.70.AEP730

AEP731

The expression of oxytocin receptor (OXTR) in metastatic pancreatic neuroendocrine tumors (PNETs)

<u>Darko Katalinic</u>¹, Stephan Bildat², Elke Kattner², Lilly Soerensen³, Ivan Aleric¹ & Aleksandar Vcev¹

¹Faculty of Dental Medicine and Health and Faculty of Medicine, Josip Juraj Strossmayer University of Osijek; ²Herford Teaching Hospital; ³Department of Cancer Medicine

Introduction

Pancreatic neuroendocrine tumors (PNETs) are rare malignant neoplasms which incidence is continually increasing. They are characterized by diverse biological behaviour and impact on the patients' prognosis, ranging from clinicaly indolent to very aggressive. Oxytocin receptor (OXTR) is a member of the family of G-protein receptors and is present on the cell-surface of the gastrointestinal organs. Unfortunately, theimpact of OXTR signaling on the development of PNETs and its underlying molecular mechanisms involved in gastrointestinal oncogenesis remains unsufficiently researched. Theaim of our study was to assess the expression of OXTR in a group of patients diagnosed with metastatic PNETs.

Material and methods

Metatatic PNETs (liver metastases) specimens (*n*=24) matched control (normal) tissue were surgically collected and mRNA expression was determined by Real-time polymerase chain reaction (Real-time-PCR). OXTR expression for tumor and control tissue was additionally analysed by immunohistochemistry.

Results

Compared to normal tissue, the OTXR showed significant overexpression in metastatic PNETs. Moreover, significant overexpression of OXTR in tumor tissue was confirmed by immunohistochemistry.

Conclusion

Our findings highlight the possibility of making OXTR a promising novel molecular target for imaging and different therapeutic approach in patients diagnosed with metastatic PNETs.

DOI: 10.1530/endoabs.70.AEP731

AEP732

Metastatic insulinoma managed with lutetium (177LU) and somatostatin analog

Mehmet Sözen, Zeynep Canturk, <u>Berrin Cetinarslan</u>, Alev Selek, Emre Gezer

Kocaeli University, Endocrinology and Metabolism, kocaeli, Turkey

Background

Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas dimension (> 2 cm), CK19 status, tumor staging and grading (Ki67>2%), and age of onset (> 50 years) can be considered elements of suspect.

Case presentation

We report a case of malignant insulinoma in a 80 year old woman presenting symptoms compatible with hypoglycemia. Low blood glucose levels (< 40 mg/dl) were documented during of these episodes. Symptoms regressed with food intake and intravenous glucose administration. No abnormality was detected in the biochemical evaluation. Prolong fasting test was performed, and the patient underwent symptomatic hypoglycemia at the 5th hour. Plasma glucose level was 39 mg/dl, insulin level 36.4 uIU/mL and C-peptide 9.28 ng/ml. Glucagon responce was measured 10 min. intervals, 85 mg/dl, 95 mg/dl and 113 mg/dl respectively. These results were suggestive of endogenous hyperinsulinemia. Magnetic resonance imaging revealed a invasive mass in the pancreatic tail location $\sim 63\times40$ mm in size and multiple metastatic nodules in the the liver. Ga-68 DOTATATE PET-CT, which showed a lesion located in the pancreatic tail location and multipl metastatic lesion in the liver, with a high somatostatin receptor density. Tru-cut biopsy made from liver lesions revealed the insulinoma tumour metastasis. Synaptophysin, pancytoceratine and chromogranin were positive. The histopathological diagnosis was suggestive of a neuroendocrine, grade-2 tumour (mitotic rate 1/10 HPF, KI-67 proliferative index 15%). Lanreotide 120 mg IM was started an every 28 days basis. The patient received 2 infusions of radiolabeled somatostatin analog lutetium (177LU) 8 weeks apart and denied any hypoglycemia. After the second administration of the lutetium, Ga-68 DOTATATE PET-CT had shown objective metabolic and radiologic response to treatment. Lutetium treatment was given as 8 cycles. Treatment of the patient with metabolic and radiological responses continues with lanreotide 90 mg/every 28 days.

Conclusions

We report a case of metastatic insulinoma treatment with somatostatin analog and Lutetium. Due to previous glycemic control reports and objective responses in unresectable cases, we decided to use Lutetium together with lanreotide. The patient's hypoglycaemia improved immediately after treatment. Unresectable metastatic insulinomas may present as a major therapeutic challenge for the physician. Treatment with landreotide and Lutetium